Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV

Overview

cited authors

Dagogo-Jack, Samuel; Frederich, Robert; Liu, Jie; Cannon, Christopher P.; Shi, Harry; Cherney, David Z., I; Cosentino, Francesco; Masiukiewicz, Urszula; Gantz, Ira; Pratley, Richard E.

authors

Pratley, Richard Edwin, MD

Publication Date

January 27, 2023

webpage

Web of Science

published in

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Journal

Research

keywords

ertugliflozin
glycated hemoglobin
insulin sparing
type 2 diabetes mellitus

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.